GERMANTOWN, Md., Jan. 24,
2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq:
PGEN) today announced it has commenced an underwritten public
offering of $75.0 million of its
common stock. In addition, Precigen intends to grant the
underwriters a 30-day option to purchase up to an additional
$11.25 million of its common stock.
The offering is subject to market and other conditions, and there
can be no assurance as to whether or when the offering may be
completed, or as to the size or terms of the offering. All of the
shares in the proposed offering are to be sold by Precigen.
J.P. Morgan Securities LLC is acting as the lead book-running
manager for the offering. Cantor Fitzgerald & Co. is also
acting as book-running manager. JMP Securities, a Citizens company,
is acting as lead manager and H.C. Wainwright & Co., LLC
is acting as co-manager.
The public offering will be made pursuant to a shelf
registration statement on Form S-3 that was previously filed with
the Securities and Exchange Commission (SEC) and became effective
on July 2, 2020. A preliminary
prospectus supplement and accompanying base prospectus relating to
and describing the terms of the offering will be filed with the SEC
and will be on the SEC's website at www.sec.gov. Copies of the
preliminary prospectus supplement and base prospectus relating to
this offering may be obtained, when available, from J.P. Morgan
Securities LLC, c/o Broadridge Financial Solutions, 1155 Long
Island Avenue, Edgewood, New York
11717, telephone: 1-866-803-9204, or by emailing at
prospectus-eq_fi@jpmchase.com. The final terms of the offering
will be disclosed in a final prospectus supplement to be filed with
the SEC.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such an
offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state or
jurisdiction.
About Precigen
Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical
stage biopharmaceutical company advancing the next generation of
gene and cell therapies using precision technology to target the
most urgent and intractable diseases in our core therapeutic areas
of immuno-oncology, autoimmune disorders, and infectious diseases.
Precigen's technologies are designed to enable us to find
innovative solutions for affordable biotherapeutics in a controlled
manner. Precigen operates as an innovation engine progressing a
preclinical and clinical pipeline of well-differentiated unique
therapies toward clinical proof-of-concept and
commercialization.
Cautionary Statement Regarding Forward-Looking
Statements
Some of the statements made in this press release are
forward-looking statements. These forward-looking statements are
based upon Precigen's current expectations and projections about
future events, including the proposed public offering. Various
factors may cause differences between Precigen's expectations and
actual results. These risks and uncertainties include, without
limitation, risks and uncertainties related to market conditions
and satisfaction of customary closing conditions related to the
proposed public offering. There can be no assurance that Precigen
will be able to complete the proposed public offering on the
anticipated terms, or at all. For further information on
potential risks and uncertainties, and other important factors, any
of which could cause Precigen's actual results to differ from those
contained in the forward-looking statements, see the section
entitled "Risk Factors" in Precigen's most recent Annual Report on
Form 10-K and subsequent reports filed with the Securities and
Exchange Commission.
Investor Contact:
Steven M. Harasym
Vice President, Investor Relations
Tel: +1 (301) 556-9850
investors@precigen.com
Media Contacts:
Donelle M. Gregory
press@precigen.com
Glenn Silver
Lazar-FINN Partners
glenn.silver@finnpartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/precigen-announces-proposed-75-0-million-public-offering-of-common-stock-301729734.html
SOURCE Precigen, Inc.